Thus, both progenitor (Knobloch et al., 2013) and cancer (Menendez and Lupu, 2007; Currie et al., 2013) cells rely on FASN activity for proliferation, and FASN inhibitors are currently under study as potential anticancer therapies (Menendez and Lupu, 2007; Currie et al., 2013). Here, FASN is linked to cancer.